M&A Deals Drop In 2015, With IVD-Sector Transactions Still Leading The Pack
This article was originally published in The Gray Sheet
There were 225 medtech M&A deals in 2015, down from 269 in 2014, according to Clinica's M&A Tracker. The in vitro diagnostics sector continues to be the most popular for transactions.
You may also be interested in...
The merger of Pfizer and Allergan might raise broader questions about the fairness – or long-term viability – of the corporate tax code in the US. But it also has generated some angst over Allergan’s future as a stalwart in ophthalmology.
The deal will make HeartWare more of a go-to firm for heart-failure specialists, executives say. It comes soon after St. Jude Medical announced its acquisition of Thoratec, another VAD-focused firm whose technology will now be sold alongside a broader set of tools for heart-failure caregivers.